Analyst Activity – HC Wainwright Initiates Coverage On Celldex Therapeutics (NASDAQ:CLDX) With a Buy

ME Staff
-
0

Analyst Ratings For Celldex Therapeutics (NASDAQ:CLDX)

Today, HC Wainwright initiated coverage on Celldex Therapeutics (NASDAQ:CLDX) with a Buy with a price target of $10.00.

There are 2 hold ratings, 6 buy ratings on the stock.

The current consensus rating on Celldex Therapeutics (NASDAQ:CLDX) is Buy (Score: 2.75) with a consensus target price of $8.08 per share, a potential 252.98% upside.

Some recent analyst ratings include

  • 8/1/2017-HC Wainwright initiated coverage with a Buy rating.
  • 6/29/2017-Aegis Reiterated Rating of Buy.
  • 6/6/2017-Cowen and Company Reiterated Rating of Buy.
  • 5/11/2017-Jefferies Group LLC Reiterated Rating of Hold.
  • 11/10/2016-Roth Capital Reiterated Rating of Buy.
  • 11/8/2016-Wedbush Reiterated Rating of Neutral.
  • 11/8/2016-Cantor Fitzgerald Reiterated Rating of Buy.

Recent Insider Trading Activity For Celldex Therapeutics (NASDAQ:CLDX)
Celldex Therapeutics (NASDAQ:CLDX) has insider ownership of 4.10% and institutional ownership of 65.85%.

  • On 9/2/2016 Tibor Keler, VP, bought 3,000 with an average share price of $3.32 per share and the total transaction amounting to $9,960.00. View SEC Filing
  • On 11/23/2015 Avery W. Catlin, CFO, sold 25,000 with an average share price of $18.00 per share and the total transaction amounting to $450,000.00. View SEC Filing
  • On 8/25/2015 Larry Ellberger, Director, bought 5,000 with an average share price of $14.00 per share and the total transaction amounting to $70,000.00. View SEC Filing
  • On 8/20/2015 Larry Ellberger, Director, bought 5,000 with an average share price of $15.00 per share and the total transaction amounting to $75,000.00. View SEC Filing
  • On 8/18/2015 Larry Ellberger, Director, bought 5,000 with an average share price of $15.95 per share and the total transaction amounting to $79,750.00. View SEC Filing
  • On 8/13/2015 Anthony S Marucci, CEO, bought 5,800 with an average share price of $16.81 per share and the total transaction amounting to $97,498.00. View SEC Filing
  • On 8/13/2015 Larry Ellberger, Director, bought 5,000 with an average share price of $16.59 per share and the total transaction amounting to $82,950.00. View SEC Filing

Recent Trading Activity for Celldex Therapeutics (NASDAQ:CLDX)
Shares of Celldex Therapeutics closed the previous trading session at 2.29 down -0.01 -0.43% with 931,317 shares trading hands.